Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Simon B AscherKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California.ORCID 0000-0003-3465-4208
Ronit KatzDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington.ORCID 0000-0001-7723-7469
Stein I HallanDepartment of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.ORCID 0000-0002-9045-3569
Michelle M EstrellaKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California.ORCID 0000-0002-8902-9576
Rebecca ScherzerKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California.
Teresa K ChenKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California.ORCID 0000-0003-0106-050
Julio A Lamprea-MontealegreKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California.ORCID 0000-0002-5999-4287
Kasey CamposKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California.ORCID 0009-0004-4754-7254
Pranav S GarimellaDivision of Nephrology-Hypertension, University of California San Diego, La Jolla, California.ORCID 0000-0002-6016-4715
Alexander L BullenDivision of Nephrology-Hypertension, University of California San Diego, La Jolla, California.ORCID 0000-0001-6864-0336
Nicholas WetterstenCardiology Section, Veterans Affairs San Diego Healthcare System, San Diego, California.ORCID 0000-0002-6122-1152
Alfred K CheungDivision of Nephrology and Hypertension, University of Utah Health, Salt Lake City, Utah.ORCID 0000-0002-7304-9476
Joachim H IxDivision of Nephrology-Hypertension, University of California San Diego, La Jolla, California.ORCID 0000-0002-8084-9869
Michael G ShlipakKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California.ORCID 0000-0002-9559-204
Funding
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Tufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025771 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CENTER, DAVID M. · 2008 to 2011
$17.6M
TUFTS CLINICAL AND TRANSLATION SCIENCE INSTITUTE (UL1): BPCAUL1RR025752 · NCRR · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2008 to 2011
key pointsAKI frequently occurs in the ambulatory setting, but there are no available tools to distinguish whether kidney function will recover. Plasma biomarkers reflecting kidney tubular injury and dysfunction measured at the time of AKI are associated with nonrecovery in kidney function. Measuring plasma biomarkers of kidney tubule health during ambulatory AKI episodes could be helpful in guiding treatment decisions.
backgroundAKI frequently occurs in the ambulatory setting, but few tools are available to distinguish whether an individual's kidney function will subsequently recover.
methodsWe included 652 participants with and without CKD in the Systolic Blood Pressure Intervention Trial who experienced ambulatory AKI, defined as a rise in serum creatinine of ≥0.3 mg/dl from baseline that occurred at the 12- or 24-month study visits. Four plasma biomarkers of kidney tubule health were measured at baseline and when ambulatory AKI was detected: kidney injury molecule-1 (KIM-1), soluble TNF receptor 1 (sTNFR1) and soluble TNF receptor 2, and uromodulin. Multivariable logistic regression models were used to evaluate biomarker associations with subsequent odds of <50% recovery in eGFR (nonrecovery) at 12 months.
resultsThe mean age was 70±10 years; eGFR at baseline was 62±25 ml/min per 1.73 m 2 , and there was an eGFR decline of 21.7±12.5 ml/min per 1.73 m 2 at the time ambulatory AKI was detected. When measured at the time of ambulatory AKI, higher KIM-1 (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.14 to 1.73) and sTNFR1 (OR, 2.07; 95% CI, 1.49 to 2.88) and lower uromodulin (OR, 0.77; 95% CI, 0.63 to 0.94) were each associated with eGFR nonrecovery in multivariable models that adjusted for eGFR and albuminuria. In models that included all four plasma biomarkers, KIM-1 and sTNFR1 remained jointly associated with eGFR nonrecovery.
conclusionsAmong hypertensive adults with ambulatory AKI, plasma biomarkers reflecting impaired kidney tubule health measured at the time of ambulatory AKI are associated with subsequent nonrecovery in kidney function.
Indexed as
Acute Kidney InjuryKidney TubulesAgedAmbulatory CareBiomarkersCreatinineFemaleGlomerular Filtration RateHepatitis A Virus Cellular Receptor 1HumansMaleMembrane GlycoproteinsMiddle AgedReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIReceptors, VirusBiomarkersCreatinineHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Membrane GlycoproteinsReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIReceptors, VirusUMOD protein, humanUromodulinAKIbiomarkershypertensionkidney tubulerenal function declinerenal tubular epithelial cells
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Plasma Biomarkers of Kidney Tubule Health during Ambulatory AKI and Kidney Function Recovery in SPRINT. · full record | OpenQuestion